SCHEMBL4063223

SCHEMBL4063223

CN(C)CCCCN1c2ccccc2N(c2ccc(Cl)cc2)S1(O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 6/20 0.39
HTR1A P08908 5/20 0.39
CYP2D6 P10635 5/20 0.39
DRD2 P14416 5/20 0.39
LMNA P02545 5/20 0.39
MAPT P10636 5/20 0.39
TP53 P04637 4/20 0.39
CYP1A2 P05177 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
SLC22A1 O15245 4/20 0.39
CHRM2 P08172 4/20 0.39
CHRM4 P08173 4/20 0.39
CHRM5 P08912 4/20 0.39
CHRM1 P11229 4/20 0.39
ADRA2B P18089 4/20 0.39
ADRA2C P18825 4/20 0.39
CHRM3 P20309 4/20 0.39
DRD1 P21728 4/20 0.39
HRH2 P25021 4/20 0.39
HTR2A P28223 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4054219 0.89 SLC6A2 (0.36) SLC6A2HTR1ACYP2D6DRD2LMNA
SCHEMBL4063225 0.85 SLC6A2 (0.51) SLC6A2HTR1ACYP2D6DRD2LMNA
SCHEMBL4055289 0.83 PIM1 (0.36) SLC6A2HTR1ADRD2HTR2ASLC6A4
SCHEMBL4054996 0.82 SLC6A2 (0.51) SLC6A2SLC6A4KCNH2SLC6A3
SCHEMBL4055117 0.82 SLC6A2 (0.36) SLC6A2HTR1ACYP2D6DRD2HTR2A
SCHEMBL4061668 0.81 SLC6A2 (0.55) SLC6A2CYP2D6DRD2CYP1A2SMN1; SMN2
Hydrochloric Acid SCHEMBL4939183 0.81 SLC6A2 (0.36) SLC6A2HTR1ADRD2HTR2ASLC6A4
SCHEMBL4938322 0.80 KMT2A (0.39) SLC6A2CYP2D6DRD2TP53CYP1A2
SCHEMBL4063154 0.80 SLC6A2 (0.49) SLC6A2HTR1ACYP2D6DRD2LMNA
SCHEMBL4061650 0.79 SLC6A2 (0.45) SLC6A2SLC6A4KCNH2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US claimed
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 SLC6A2 2/4885HTR1A 11/4885CYP2D6 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.